Hemodialysis is the most effective life-sustaining treatment for patients with end-stage renal failure. Making more kidney disease patients receive more effective treatment and improving the survival time and quality of life of kidney disease patients is the current focus of research in the medical field of kidney disease, and hemodialysis is also one of the largest medical projects invested by the state during the 12th Five-Year Plan. Conventional hemodialysis treatment does not remove enough middle-molecule toxins and is prone to complications; while hemodialysis filtration (HDF) can effectively remove middle-molecule substances, reduce dialysis complications, prolong survival and reduce mortality, but it cannot be widely used for a long time because of the special HDF equipment, the need to use multi-pump dialysis machines, the large investment in equipment, the use of replacement fluid in treatment, the high consumption cost and the complicated operation of personnel. It is not widely used in the long term because of the special HDF equipment, the need to use multi-pump dialysis machines, the large investment in equipment, the use of replacement fluid in treatment, the high consumption cost, and the complicated personnel operation. High-flux dialysis (HFHD) is defined as dialysis using a high-flux dialysis machine with an ultrafiltration coefficient (Kuf) > 20 ml/(h?mmHg). HFHD has a similar clearance of small molecules, represented by urea, and an increased clearance of medium and large molecules, represented by b2-microglobulin (b2-M), to that of regular dialysis. The MPO (membrane permeability outcome) study published in Europe in 2009 showed that people with serum albumin levels <40 g/L and diabetic patients could benefit from HFHD compared to low-flux dialysis (LFHD) treatment. 2010 The domestic Northern Medical Study showed that single HFHD treatment did not clear b2-M as well as hemodiafihration (HDF), but the amount of b2-M cleared by 3 weekly HFHD treatments was significantly higher than 1 weekly HDF, and after 6 months of observation, patients' blood pressure was easily controlled, serum b2-M and C-reactive protein (CRP) levels decreased, serum After 6 months of observation, the patients' blood pressure was easily controlled, serum b2-M and C-reactive protein (CRP) levels decreased, serum albumin gradually increased, and the percentage of hemoglobin compliance increased. The mechanism by which HFHD reduces cardiovascular and cerebrovascular comorbidities, reduces all-cause mortality, and improves survival prognosis in hemodialysis patients is thought to be related to the reduction of traditional risk factors and dialysis-related risk factors. HFHD has a better cost effectiveness, and although clearing b2-M single HDF and HF is better than HFHD, for economic reasons, most patients in China currently do not enjoy the benefits of long-term treatment with HDF and HF, and can afford at most 1 treatment every 1-2 weeks, and the rest use ordinary dialysis, which does not play the proper role of HDHF and HF; and implementing HFHD treatment for them is economically and technically feasible and beneficial to patients' long-term survival.